SCHEMBL21324902

SCHEMBL21324902

CC(=O)NC[C@H]1CN(c2ccc(-c3cccnc3)cc2)C(=O)O1

nearest known ligand 0.62

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.51
MAOA P21397 5/20 0.51
MAOB P27338 2/20 0.51
LMNA P02545 1/20 0.51
PTGS1 P23219 1/20 0.51
CALML3 P27482 1/20 0.51
SDHA P31040 1/20 0.51
F10 P00742 5/20 0.49
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
GRM2 Q14416 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10423881 1.00 ABCB11 (0.51) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL10435848 0.93 MAOA (0.50) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL8489164 0.88 MAOA (0.55) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL8489161 0.88 MAOA (0.55) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL9550299 0.88 MAOA (0.57) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL9550276 0.88 MAOA (0.57) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL13298924 0.88 MAOA (0.61) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL8339574 0.87 MAOA (0.51) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL8311415 0.87 MAOA (0.55) ABCB11MAOAMAOBLMNAPTGS1
SCHEMBL8484607 0.86 MAOA (0.66) MAOAMAOBLMNAPTGS1CALML3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2023-10-05 US disclosed
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2023-10-05 US disclosed
US-20190270723-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2019-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270723-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF NSUN3, NSUN2, TARBP1 ABCB11 4278/4885MAOA 2886/4885MAOB 1343/4885
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF NSUN3, NSUN2, TARBP1 ABCB11 4278/4885MAOA 2886/4885MAOB 1343/4885
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof NSUN3, NSUN2, TARBP1 ABCB11 4278/4885MAOA 2886/4885MAOB 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.